The dual target inhibitor of mutant IDH1 and mutant IDH2, AG-881, is an orally available inhibitor that can pass the blood-brain barrier and may serve as a better option for glioma patients (Medeiros et al., 2017). This evidence concerns the gene IDH2 and central nervous system cancer.